Drug-enhanced Cell Therapy Programs
Adoptive Cell Therapy
Nurix is pioneering applying targeted protein modulation to adoptive cell therapy. Our lead cell therapy program applies a CBL-B inhibitor, NX-0255, to a cancer patient’s T cells outside the body (ex vivo) to enhance their tumor-killing ability when returned to the patient as an autologous cell therapy. Inhibiting CBL-B has several beneficial effects that enhance adoptive T cell therapy, including stimulation of IL-2 secretion, increased T cell proliferation, reduced T cell exhaustion, and a skewing of the phenotype of the T-cells for improved clinical outcomes.
| Drug Candidate | Target (Delivery) | Therapeutic Area | Discovery | Lead Optimization | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|---|---|
| Protein Degradation Chimeric Targeting Molecule (CTM) Portfolio | ||||||||
| NX-2127 | BTK + IMiD Activity (Oral) | B-cell malignancies |
| |||||
| NX-5948 | BTK (Oral) | B-cell malignancies and autoimmune disease |
| |||||
| KINASE-CTM3 | Undisclosed | T-cell malignancies and autoimmune disease |
| |||||
| COVID-CTMs | 3 targets | Anti-viral |
| |||||
| Drug Candidate | Target (Delivery) | Therapeutic Area | Discovery | Lead Optimization | Preclinical | Phase 1 | Phase 2 | Phase 3 |
| Ligase Inhibitor Portfolio | ||||||||
| NX-1607 | CBL-B (Oral) | Immuno-oncology |
| |||||
| DeTIL-0255 | CBL-B (ex vivo) | Tumor infiltrating lymphocytes |
| |||||
| LIGASE-INH2 | Undisclosed | Immuno-oncology |
| |||||
| Drug Candidate | Target (Delivery) | Therapeutic Area | Discovery | Lead Optimization | Preclinical | Phase 1 | Phase 2 | Phase 3 |
| Partners and Subsidiaries | ||||||||
| DeCART | CBL-B and others (ex vivo) | Chimeric antigen receptor T‑cells (CAR-T) |
| |||||
| Gilead Sciences | 5 targets | Undisclosed | Undisclosed Progress
| |||||
| Sanofi | 5 targets | Undisclosed | Undisclosed Progress
| |||||
| Candidate / Target | Phase |
|---|---|
| Protein Degradation Chimeric Targeting Molecule (CTM) Portfolio | NX-2127 BTK + IMiD Activity (Oral) | Phase 1 |
| NX-5948 BTK (Oral) | Preclinical |
| KINASE-CTM3 Undisclosed | Lead Optimization |
| COVID-CTMs 3 targets | Discovery |
| Ligase Inhibitor Portfolio | NX-1607 CBL-B (Oral) | Preclinical |
| DeTIL-0255 CBL-B (ex vivo) | Preclinical |
| LIGASE-INH2 Undisclosed | Lead Optimization |
| Partners and Subsidiaries | DeCART CBL-B and others (ex vivo) | Lead Optimization |
| Gilead Sciences 5 targets | Undisclosed Progress |
| Sanofi 5 targets | Undisclosed Progress |
DeTIL-0255 (drug-enhanced tumor-infiltrating lymphocytes for solid tumors)
DeTIL-0255 is a cellular therapy that incorporates our proprietary small molecule CBL-B inhibitor NX-0255 in the cell expansion process of tumor infiltrating lymphocytes (TIL). We call this drug-enhanced TIL, or DeTIL. While DeTIL-0255 incorporates a CBL-B inhibitor, we are also exploring combining other targeted agents, such as its proprietary protein degraders, to enhance T cell expansion and phenotypes.
We are planning to first develop DeTIL-0255 in multiple solid tumors as a monotherapy and later to combine it with our proprietary oral CBL-B inhibitor, NX-1607. A Phase 1 clinical trial of DeTIL-0255 in gynecological malignancies is planned to start in the second half of 2021.
DeCART (drug-enhanced chimeric antigen receptor T cells)
Nurix has established a subsidiary, DeCART, focused on drug-enhanced CAR T therapies for hematological and solid tumors. DeCART was founded by Nurix and world-renowned physician and scientist Dr. Carl June, in collaboration with his colleagues from the University of Pennsylvania.
Visit DeCART
'